Drugs / Lactobacillus casei Shirota
last change Mar 2025 re-read 2 minutes ago

Lactobacillus casei Shirota

Other / unclassified

Developed for
respiratory tract infectious disorder · colorectal cancer
Investigated by
University of Antwerp · Yakult Honsha Co., LTD

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00849277 Oct 2006 → Apr 2008 respiratory tract infectious disorder University of Antwerp Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT07144475 Comparator Jan → Nov 2024 colorectal cancer Dharmais National Cancer Center Hospital Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lactobacillus casei Shirota ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144475
1

NCT00849277

Known as Lactobacillus casei strain Shirota Lactobacillus casei strain Shirota (LcS) is widely consumed in fermented milk products.” NCT00849277
Known as LcS “We assessed whether an intervention with Lactobacillus casei Shirota (LcS) in elderly nursing home residents reduced their susceptibility to respiratory symptoms and improved...” PMID 22440853 Mar 2012
Modality Other / unclassified “The aim of this multicentre, randomized, placebo controlled, double blind study (RCT) is to assess if probiotic treatment with Lactobacillus casei Shirota improves the...” NCT00849277